Last week, ARDAT project members gathered in Barcelona for the project’s General Assembly. The ARDAT project is focused on accelerating the research and development of Advanced Therapy Medicinal Products (ATMPs) by addressing knowledge gaps in immunology and gene therapy vector metabolism, and by identifying opportunities for regulatory harmonisation. The ultimate goal is to help bring safer, more effective life-changing therapies to patients sooner.
ASPHALION is proud to be a partner in the ARDAT project and co-leader of the regulatory work package, which focuses on engaging with regulators and contributing to recommendations for regulatory alignment. ASPHALION experts Christopher Mann, Jon Giblin, and Montse Domingo participated in the meeting, with Christopher presenting a summary of progress over the past year and outlining next steps.
A key highlight of this year’s meeting was a panel discussion on patient involvement in ATMP development. The session featured insightful contributions from:
- Dr. Amy Hunter (Genetic Alliance, UK)
- Dr. Sandra Silva and Dr. Christian Brander (GRIN)
- Dr. Francina Munell (Vall d’Hebron University Hospital)
Their perspectives emphasized the critical role of early and meaningful patient engagement to ensure that therapies under development align with patient needs and expectations.
Our sincere thanks to the attendees who joined us in Barcelona under less-than-easy conditions, and all speakers for showcasing the progress made across the various work packages.
The ARDAT project is funded by the Innovative Health Initiative (IHI), a public-private partnership of the EU. It brings together academia, SMEs, and EFPIA members in a collaborative effort to advance ATMP development.
Need support with your EU-funded projects or regulatory strategy? Contact us at: [email protected]
